Literature DB >> 33567543

Implication between Genetic Variants from APOA5 and ZPR1 and NAFLD Severity in Patients with Hypertriglyceridemia.

Virginia Esteve-Luque1,2,3, Ariadna Padró-Miquel2,4,5, Marta Fanlo-Maresma1,2,3, Emili Corbella1,2,5, Xavier Corbella1,2,6, Xavier Pintó1,2,5,7, Beatriz Candás-Estébanez2,4,5,8.   

Abstract

BACKGROUND: Lipid metabolism disorders, especially hypertriglyceridemia (HTG), are risk factors for non-alcoholic fatty liver disease (NAFLD). However, the association between genetic factors related to HTG and the risk of NAFLD has been scarcely studied.
METHODS: A total of 185 subjects with moderate HTG were prospectively included. We investigated the association between genetic factors' (five allelic variants with polygenic hypertriglyceridemia) clinical and biochemical biomarkers with NAFLD severity. The five allelic variants' related clinical and biochemical data of HTG were studied in all the subjects. NAFLD was assessed by abdominal ultrasound and patients were divided into two groups, one with no or mild NAFLD and another with moderate/severe NAFLD.
RESULTS: Patients with moderate/severe NAFLD had higher weight and waist values and a higher prevalence of insulin resistance than patients with no or mild NAFLD. Moderate/severe NAFLD was independently associated with APOA5 rs3134406 and ZPR1 rs964184 variants, and also showed a significant inverse relationship with lipoprotein(a) [Lp(a)] concentrations.
CONCLUSIONS: APOA5 rs3135506 and ZPR1 rs964184 variants and lipoprotein(a) are associated with moderate/severe NAFLD. This association was independent of body weight, insulin resistance, and other factors related to NAFLD.

Entities:  

Keywords:  APOA5 variant; Lp(a); SNP; ZPR1 variant; hypertriglyceridemia; non-alcoholic fatty liver disease (NAFLD)

Mesh:

Substances:

Year:  2021        PMID: 33567543      PMCID: PMC7914661          DOI: 10.3390/nu13020552

Source DB:  PubMed          Journal:  Nutrients        ISSN: 2072-6643            Impact factor:   5.717


  41 in total

Review 1.  Apolipoprotein A-V; a potent triglyceride reducer.

Authors:  Stefan K Nilsson; Joerg Heeren; Gunilla Olivecrona; Martin Merkel
Journal:  Atherosclerosis       Date:  2011-07-23       Impact factor: 5.162

2.  Insulin resistance index (HOMA-IR) in the differentiation of patients with non-alcoholic fatty liver disease and healthy individuals.

Authors:  Ana Lúcia Farias de Azevedo Salgado; Luciana de Carvalho; Ana Claudia Oliveira; Virgínia Nascimento dos Santos; Jose Gilberto Vieira; Edison Roberto Parise
Journal:  Arq Gastroenterol       Date:  2010 Apr-Jun

3.  Prospective evaluation of the diagnostic accuracy of liver ultrasonography.

Authors:  J C Debongnie; C Pauls; M Fievez; E Wibin
Journal:  Gut       Date:  1981-02       Impact factor: 23.059

4.  Homozygosity for a partial deletion of apoprotein A-V signal peptide results in intracellular missorting of the protein and chylomicronemia in a breast-fed infant.

Authors:  Kirstin Albers; Christian Schlein; Kirsten Wenner; Peter Lohse; Alexander Bartelt; Joerg Heeren; René Santer; Martin Merkel
Journal:  Atherosclerosis       Date:  2014-01-08       Impact factor: 5.162

5.  A functional variant in APOA5/A4/C3/A1 gene cluster contributes to elevated triglycerides and severity of CAD by interfering with microRNA 3201 binding efficiency.

Authors:  Guanglin Cui; Zongzhe Li; Rui Li; Jin Huang; Haoran Wang; Lina Zhang; Hu Ding; Dao Wen Wang
Journal:  J Am Coll Cardiol       Date:  2014-07-22       Impact factor: 24.094

Review 6.  Hypertriglyceridemia: its etiology, effects and treatment.

Authors:  George Yuan; Khalid Z Al-Shali; Robert A Hegele
Journal:  CMAJ       Date:  2007-04-10       Impact factor: 8.262

7.  Serum lipoprotein(a) levels and insulin resistance have opposite effects on fatty liver disease.

Authors:  Inha Jung; Hyemi Kwon; Se Eun Park; Cheol-Young Park; Won-Young Lee; Ki-Won Oh; Sung-Woo Park; Eun-Jung Rhee
Journal:  Atherosclerosis       Date:  2020-07-30       Impact factor: 5.162

Review 8.  The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD).

Authors:  Elena Buzzetti; Massimo Pinzani; Emmanuel A Tsochatzis
Journal:  Metabolism       Date:  2016-01-04       Impact factor: 8.694

Review 9.  Nonalcoholic fatty liver disease: Evolving paradigms.

Authors:  Amedeo Lonardo; Fabio Nascimbeni; Mauro Maurantonio; Alessandra Marrazzo; Luca Rinaldi; Luigi Elio Adinolfi
Journal:  World J Gastroenterol       Date:  2017-09-28       Impact factor: 5.742

10.  Evaluation of Polygenic Determinants of Non-Alcoholic Fatty Liver Disease (NAFLD) By a Candidate Genes Resequencing Strategy.

Authors:  Alessia Di Costanzo; Francesca Belardinilli; Diego Bailetti; Marialuisa Sponziello; Laura D'Erasmo; Licia Polimeni; Francesco Baratta; Daniele Pastori; Fabrizio Ceci; Anna Montali; Gabriella Girelli; Bruna De Masi; Antonio Angeloni; Giuseppe Giannini; Maria Del Ben; Francesco Angelico; Marcello Arca
Journal:  Sci Rep       Date:  2018-02-27       Impact factor: 4.379

View more
  2 in total

Review 1.  The Role of Hydrogen Sulfide Regulation of Autophagy in Liver Disorders.

Authors:  Xueqin Lu; Yueming Ding; Huiyang Liu; Mengyao Sun; Chaoran Chen; Yihan Yang; Honggang Wang
Journal:  Int J Mol Sci       Date:  2022-04-06       Impact factor: 5.923

2.  A Gene Variation at the ZPR1 Locus (rs964184) Interacts With the Type of Diet to Modulate Postprandial Triglycerides in Patients With Coronary Artery Disease: From the Coronary Diet Intervention With Olive Oil and Cardiovascular Prevention Study.

Authors:  Juan F Alcala-Diaz; Antonio P Arenas-de Larriva; Jose D Torres-Peña; Fernando Rodriguez-Cantalejo; Oriol A Rangel-Zuñiga; Elena M Yubero-Serrano; Francisco M Gutierrez-Mariscal; Magdalena P Cardelo; Raul M Luque; Jose M Ordovas; Pablo Perez-Martinez; Javier Delgado-Lista; Jose Lopez-Miranda
Journal:  Front Nutr       Date:  2022-06-17
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.